The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic Name||Therapeutic Area||Recommendation Type||Project Status Sort descending||Date Submission Received||Date Recommendation Issued|
|Xofluza||baloxavir marboxil||Influenza||CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer|
|Imbruvica||ibrutinib||CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer|
|TBC||filgrastim||Prevention or treatment of neutropenia in various indications||Cancelled|
|Xolair||Omalizumab||Asthma, severe persistent||Cancelled|